Market research
ALCJ.PA Crossject Société Anonyme
PA EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 83M
- P/E ratio
- Not available
- Analyst target
- 4.4
- Dividend yield
- Not available
- Beta
- 0.5
Profile
Company facts
- Exchange
- PA
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- ISIN
- FR0011716265
- Market cap
- 83M
- P/E ratio
- Not available
- Analyst target
- 4.4
- Dividend yield
- Not available
- Beta
- 0.5
About
About Crossject Société Anonyme
Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, needle-free, pre-filled, single-use auto-injector. It offers Midazolam for epileptic seizure; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster headaches, as well as Hydrocortisone for acute adrenal crisis and Methotrexate for the treatment of rheumatoid arthritis. In addition, the company is developing ZEPIZURE, an emergency treatment for managing epileptic seizures. The company was incorporated in 2001 and is based in Dijon, France.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ALCJ.PA discussion.
5 years, 5 months ago
Crossject Société Anonyme is currently in a long term downtrend where the price is trading 8.6% below its 200 day moving average.
From a valuation standpoint, the stock is 57.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 117.0.
Based on the above factors, Crossject Société Anonyme gets an overall score of 1/5.